Cost Comparison

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pharmacoeconomic Review Report: Nusinersen (Spinraza): (Biogen Canada Inc.): Indication: Treatment of patients with 5q SMA [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan.

Cover of Pharmacoeconomic Review Report: Nusinersen (Spinraza)

Pharmacoeconomic Review Report: Nusinersen (Spinraza): (Biogen Canada Inc.): Indication: Treatment of patients with 5q SMA [Internet].

Show details

Contents

< Prev Next >

Appendix 1Cost Comparison

The comparators presented in the table below have been deemed to be appropriate by clinical experts. Comparators may be recommended (appropriate) practice, versus actual practice. Comparators are not restricted to drugs, but may be devices or procedures. Costs are manufacturer list prices, unless otherwise specified. Existing Product Listing Agreements are not reflected in the table and as such may not represent the actual costs to public drug plans.

Table 6CDR Cost Comparison Table for the Treatment of Spinal Muscular Atrophy

Drug/Comparator	Strength	Dosage Form	Price ($)	Recommended Dosage	Average Weekly Drug Cost ($)	Average Annual Drug Cost ($)
Nusinersen (Spinraza)	12 mg – 5 ml vial	intrathecal injection	118,000^†	Day 1, 15, 30 and 60 then every 4 months	Year 1: 13,578 Subsequent years: 6,789	Year 1; 708,000 Subsequent years: 354,000

: mg = milligrams; ml – milliliters
†: Unit prices of nusinersen as provided by manufacturer

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK534119

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Pharmacoeconomic Review Report: Nusinersen (Spinraza): (Biogen Canada Inc.): Indication: Treatment of patients with 5q SMA [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan. Appendix 1, Cost Comparison.
PDF version of this title (923K)
Disable Glossary Links